For example, prophylactic treatment with an S100A9 inhibitor has been shown to reduce colitis-induced neuroinflammation (154) and NLRP3−/− mice showed attenuated neuroinflammation and neurological dysfunction following DSS (166). Here, S100A9 is linked to colitis.